← Leaderboards
Padmini Salgame
Rutgers Biomedical And Health Sciences
$42,479,907
Attributed
$75,592,395
Total exposure
28
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11.2M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$112,792,017 · 30
By mechanism
U19$67,032,035 · 9
R01$36,314,722 · 12
UC7$4,923,809 · 1
R21$1,276,058 · 3
UH2$1,139,842 · 1
R56$774,400 · 1
Top collaborators
- David Alland74 shared
- Jerrold J. Ellner31 shared
- C Robert Horsburgh13 shared
- Veronique Dartois8 shared
- David Louis Horn8 shared
- Gloria Marcela Rodriguez6 shared
- William Evan Johnson3 shared
- Lanbo Shi3 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- David Alland$97,558,393
- Edmund C. Lattime$9,980,995
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisMycobacterium TuberculosisInfectionPreventBacteriaPharmaceutical PreparationsTuberculosis TreatmentResponseImmune ResponseImmuneBiological MarkersImmunityIn VivoCellsPathogenRelapseProgramsCytokineMacrophageBrazilDrug ResistancePhenotypeT-LymphocyteNovel Therapeutics
Grant awards (143)
Bacterial and Host Heterogeneity in TB latency, persistence and progression$2,722,689
U19 · FY2025 · AI
Bacteria and Host in TB Transmission$1,612,367
R01 · FY2025 · AI
Animal models and related services (AMRS) core$1,538,028
UC7 · FY2025 · AI · contact PI
Host-bacterial interactions determining the spectrum of Mtb transmission$1,041,944
R01 · FY2025 · AI · contact PI
Biomarker Signatures of TB Infection in Young Children With and Without HIV$1,016,533
R01 · FY2025 · AI · contact PI
One-carbon metabolism and immune cell function in tuberculosis$769,711
R01 · FY2025 · AI
Mechanisms of IFNg-independent T cell and B cell-mediated protection in TB.$769,589
R01 · FY2025 · AI · contact PI
Role of mycobacterial dynamin-like proteins in the biogenesis of membrane vesicles, and host-pathogen interactions$614,027
R01 · FY2025 · AI
Immune Determinants of the Course of Mycobacterium tuberculosis infection and Disease$610,717
U19 · FY2025 · AI · contact PI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$38,013
U19 · FY2025 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$8,125
U19 · FY2025 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$2,749,420
U19 · FY2024 · AI
Animal models and related services (AMRS) core$1,687,027
UC7 · FY2024 · AI · contact PI
Novel and Optimized Diagnostics for Pediatric TB$1,142,223
R01 · FY2024 · AI
Biomarker Signatures of TB Infection in Young Children With and Without HIV$1,028,909
R01 · FY2024 · AI · contact PI
Immune Determinants of the Course of Mycobacterium tuberculosis infection and Disease$935,638
U19 · FY2024 · AI · contact PI
Mechanisms of IFNg-independent T cell and B cell-mediated protection in TB.$800,200
R01 · FY2024 · AI · contact PI
One-carbon metabolism and immune cell function in tuberculosis$769,821
R01 · FY2024 · AI
Role of mycobacterial dynamin-like proteins in the biogenesis of membrane vesicles, and host-pathogen interactions$614,027
R01 · FY2024 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$2,658,286
U19 · FY2023 · AI
Animal models and related services (AMRS) core$1,698,754
UC7 · FY2023 · AI · contact PI
Bacteria and Host in TB Transmission$1,697,099
R01 · FY2023 · AI
Biomarker Signatures of TB Infection in Young Children With and Without HIV$1,127,706
R01 · FY2023 · AI · contact PI
Novel and Optimized Diagnostics for Pediatric TB$1,088,847
R01 · FY2023 · AI
One-carbon metabolism and immune cell function in tuberculosis$784,181
R01 · FY2023 · AI
Immune Determinants of the Course of Mycobacterium tuberculosis infection and Disease$752,167
U19 · FY2023 · AI · contact PI
Role of mycobacterial dynamin-like proteins in the biogenesis of membrane vesicles, and host-pathogen interactions$650,180
R01 · FY2023 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$339,935
U19 · FY2023 · AI
Novel and Optimized Diagnostics for Pediatric TB$219,999
R01 · FY2023 · AI
Complementary diagnostic biomarkers of sputum culture-negative TB [R21]$196,250
R21 · FY2023 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$2,658,286
U19 · FY2022 · AI
Bacteria and Host in TB Transmission$1,816,206
R01 · FY2022 · AI
Novel and Optimized Diagnostics for Pediatric TB$1,122,443
R01 · FY2022 · AI
Role of mycobacterial dynamin-like proteins in the biogenesis of membrane vesicles, and host-pathogen interactions$646,940
R01 · FY2022 · AI
Immune Determinants of the Course of Mycobacterium tuberculosis infection and Disease$397,982
U19 · FY2022 · AI · contact PI
Complementary diagnostic biomarkers of sputum culture-negative TB [R21]$235,007
R21 · FY2022 · AI
Novel and Optimized Diagnostics for Pediatric TB$219,999
R01 · FY2022 · AI
Bacteria and Host in TB Transmission$219,999
R01 · FY2022 · AI
Role of mycobacterial dynamin-like proteins in the biogenesis of membrane vesicles, and host-pathogen interactions$204,637
R01 · FY2022 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$2,751,534
U19 · FY2021 · AI
Bacteria and Host in TB Transmission$1,695,066
R01 · FY2021 · AI
Novel and Optimized Diagnostics for Pediatric TB$1,119,258
R01 · FY2021 · AI
Role of mycobacterial dynamin-like proteins in the biogenesis of membrane vesicles, and host-pathogen interactions$669,830
R01 · FY2021 · AI
Immune Determinants of the Course of Mycobacterium tuberculosis infection and Disease$507,661
U19 · FY2021 · AI · contact PI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,457,326
U19 · FY2020 · AI
Administrative Core$2,264,304
U19 · FY2020 · AI
Bacteria and Host in TB Transmission$1,637,992
R01 · FY2020 · AI
Novel and Optimized Diagnostics for Pediatric TB$1,085,066
R01 · FY2020 · AI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$770,673
U19 · FY2020 · AI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$661,749
U19 · FY2020 · AI · contact PI
Clinical Core$618,699
U19 · FY2020 · AI
Validation and Application of a Model for Human-like TB Latency in Rabbits$525,694
U19 · FY2020 · AI
Program in Infection, Immunity and Inflammation$150,562
T32 · FY2020 · AI · contact PI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,665,571
U19 · FY2019 · AI
Administrative Core$1,947,556
U19 · FY2019 · AI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$777,574
U19 · FY2019 · AI
Validation and Application of a Model for Human-like TB Latency in Rabbits$470,784
U19 · FY2019 · AI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$267,556
U19 · FY2019 · AI · contact PI
Clinical Core$202,101
U19 · FY2019 · AI
Program in Infection, Immunity and Inflammation$131,508
T32 · FY2019 · AI · contact PI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$2,399,184
U19 · FY2018 · AI
Administrative Core$1,965,726
U19 · FY2018 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$1,413,190
U19 · FY2018 · AI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$532,945
U19 · FY2018 · AI · contact PI
Administrative Core$515,303
U19 · FY2018 · AI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$385,878
U19 · FY2018 · AI
Validation and Application of a Model for Human-like TB Latency in Rabbits$348,070
U19 · FY2018 · AI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$344,415
U19 · FY2018 · AI · contact PI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$264,427
U19 · FY2018 · AI
Validation and Application of a Model for Human-like TB Latency in Rabbits$158,055
U19 · FY2018 · AI
Program in Infection, Immunity and Inflammation$128,591
T32 · FY2018 · AI · contact PI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$106,673
U19 · FY2018 · AI
Clinical Core$24,317
U19 · FY2018 · AI
Clinical Core$15,491
U19 · FY2018 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,064,926
U19 · FY2017 · AI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$924,431
U19 · FY2017 · AI · contact PI
Administrative Core$838,137
U19 · FY2017 · AI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$587,529
U19 · FY2017 · AI
Validation and Application of a Model for Human-like TB Latency in Rabbits$454,429
U19 · FY2017 · AI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$216,253
U19 · FY2017 · AI
The in vivo effect of vitamin D on Mycobacterium tuberculosis infection$189,878
R21 · FY2017 · AI · contact PI
Program in Infection, Immunity and Inflammation$169,054
T32 · FY2017 · AI · contact PI
Clinical Core$44,147
U19 · FY2017 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,078,872
U19 · FY2016 · AI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$1,054,927
U19 · FY2016 · AI · contact PI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$1,028,211
U19 · FY2016 · AI
Autophagy-based HDT for tuberculosis$561,389
UH2 · FY2016 · AI
Validation and Application of a Model for Human-like TB Latency in Rabbits$543,503
U19 · FY2016 · AI
Administrative Core$516,336
U19 · FY2016 · AI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$255,998
U19 · FY2016 · AI
The in vivo effect of vitamin D on Mycobacterium tuberculosis infection$229,628
R21 · FY2016 · AI · contact PI
Program in Infection, Immunity and Inflammation$167,032
T32 · FY2016 · AI · contact PI
Clinical Core$74,224
U19 · FY2016 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,050,511
U19 · FY2015 · AI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$1,192,956
U19 · FY2015 · AI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$757,912
U19 · FY2015 · AI
Administrative Core$725,396
U19 · FY2015 · AI
Validation and Application of a Model for Human-like TB Latency in Rabbits$606,449
U19 · FY2015 · AI
Autophagy-based HDT for tuberculosis$578,453
UH2 · FY2015 · AI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$468,455
U19 · FY2015 · AI · contact PI
TLR2 and the Tubercle Granuloma$397,500
R01 · FY2015 · AI · contact PI
Clinical Core$27,211
U19 · FY2015 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,143,754
U19 · FY2014 · AI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$1,086,119
U19 · FY2014 · AI
Administrative Core$634,424
U19 · FY2014 · AI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$510,579
U19 · FY2014 · AI · contact PI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$435,831
U19 · FY2014 · AI
TLR2 and the Tubercle Granuloma$397,500
R01 · FY2014 · AI · contact PI
Validation and Application of a Model for Human-like TB Latency in Rabbits$382,748
U19 · FY2014 · AI
Clinical Core$94,053
U19 · FY2014 · AI
TLR2 and the Tubercle Granuloma$190,557
R01 · FY2013 · AI · contact PI
TLR2 and the Tubercle Granuloma$179,948
R01 · FY2013 · AI · contact PI
TLR2 and the Tubercle Granuloma$390,000
R01 · FY2012 · AI · contact PI
Heminth Modulation of Mtb$564,154
R01 · FY2011 · AI · contact PI
TLR2 and the Tubercle Granuloma$195,000
R01 · FY2011 · AI · contact PI
Heminth Modulation of Mtb$554,354
R01 · FY2010 · AI · contact PI
TLR2 and the Tubercle Granuloma$390,000
R56 · FY2010 · AI · contact PI
Heminth Modulation of Mtb$96,272
R01 · FY2010 · AI · contact PI
Heminth Modulation of Mtb$544,746
R01 · FY2009 · AI · contact PI
BD Facsaria for use in BSL3$464,744
S10 · FY2009 · RR · contact PI
TLR2 and the Tubercle Granuloma$384,400
R56 · FY2009 · AI · contact PI
Heminth Modulation of Mtb$529,987
R01 · FY2008 · AI · contact PI
TLR2 Regulation of Host Immune Response in TB$191,295
R21 · FY2008 · AI · contact PI
Heminth Modulation of Mtb$524,720
R01 · FY2007 · AI · contact PI
Induction of Th1 Immunity in Tuberculosis$368,605
R01 · FY2007 · AI · contact PI
TLR2 Regulation of Host Immune Response in TB$234,000
R21 · FY2007 · AI · contact PI
Induction of Th1 Immunity in Tuberculosis$379,614
R01 · FY2006 · AI · contact PI
Th1 Cell Apoptosis in Tuberculosis$577,812
R01 · FY2005 · AI
Induction of Th1 Immunity in Tuberculosis$388,750
R01 · FY2005 · AI
Th1 Cell Apoptosis in Tuberculosis$574,996
R01 · FY2004 · AI
Induction of Th1 Immunity in Tuberculosis$388,750
R01 · FY2004 · AI
Th1 Cell Apoptosis in Tuberculosis$40,320
R03 · FY2004 · TW
Th1 Cell Apoptosis in Tuberculosis$526,052
R01 · FY2003 · AI
Induction of Th1 Immunity in Tuberculosis$376,250
R01 · FY2003 · AI
Th1 Cell Apoptosis in Tuberculosis$39,020
R03 · FY2003 · TW
Th1 Cell Apoptosis in Tuberculosis$1,300
R03 · FY2003 · TW
Th1 Cell Apoptosis in Tuberculosis$519,276
R01 · FY2002 · AI
Th1 Cell Apoptosis in Tuberculosis$65,171
R01 · FY2002 · AI
Th1 Cell Apoptosis in Tuberculosis$39,020
R03 · FY2002 · TW
Th1 Cell Apoptosis in Tuberculosis$517,378
R01 · FY2001 · AI
REGULATION OF GRANULOMA IN TUBERCULOSIS$446,520
R01 · FY2001 · HL
REGULATION OF GRANULOMA IN TUBERCULOSIS$406,761
R01 · FY2000 · HL
REGULATION OF GRANULOMA IN TUBERCULOSIS$29,250
R01 · FY2000 · HL